Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.94 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | NNMT | P40261 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30056154 | 0.98 | L3MBTL1 (0.97) | NPSR1L3MBTL1KMT2AMEN1HSP90AA1 | |
| SCHEMBL1982654 | 0.98 | L3MBTL1 (0.97) | NPSR1L3MBTL1KMT2AMEN1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL34474900 | 0.97 | L3MBTL1 (0.94) | NPSR1L3MBTL1KMT2AMEN1HSP90AA1 | |
| Iodide SCHEMBL15899403 | 0.97 | L3MBTL1 (1.00) | NPSR1L3MBTL1KMT2AMEN1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL1527128 | 0.97 | L3MBTL1 (0.94) | NPSR1L3MBTL1KMT2AMEN1HSP90AA1 | |
| SCHEMBL13934018 | 0.92 | NPSR1 (0.84) | NPSR1L3MBTL1KMT2AMEN1HSP90AA1 | |
| Bromide SCHEMBL5146810 | 0.90 | NPSR1 (0.77) | NPSR1L3MBTL1KMT2AMEN1HSP90AA1 | |
| Bromide SCHEMBL5148024 | 0.90 | NPSR1 (0.77) | NPSR1L3MBTL1KMT2AMEN1HSP90AA1 | |
| Bromide SCHEMBL5148142 | 0.89 | NPSR1 (0.76) | NPSR1L3MBTL1KMT2AMEN1HSP90AA1 | |
| SCHEMBL3913983 | 0.88 | NPSR1 (0.78) | NPSR1L3MBTL1KMT2AMEN1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010123963-A2 | UTILIZING ELECTROMAGNETIC RADIATION TO ACTIVATE FILTERCAKE BREAKERS DOWNHOLE | HORTON AMY C (US) | 2010-10-28 | — | — | WO | claimed |
| US-20100263867-A1 | UTILIZING ELECTROMAGNETIC RADIATION TO ACTIVATE FILTERCAKE BREAKERS DOWNHOLE | HORTON AMY C | 2010-10-21 | — | — | US | claimed |
| EP-1355645-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON INC (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040097495-A1 | Method for treating fibrotic diseases or other indications IIIC | WAGLE DILIP (US) | 2004-05-20 | — | — | US | claimed |
| EP-1355645-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | Alteon, Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| US-20020183365-A1 | Method for treating fibrotic diseases or other indications IIIC | ALTEON, INC. | 2002-12-05 | — | — | US | claimed |
| WO-2002067851-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| WO-2010123963-A2 | UTILIZING ELECTROMAGNETIC RADIATION TO ACTIVATE FILTERCAKE BREAKERS DOWNHOLE | HORTON AMY C (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100263867-A1 | UTILIZING ELECTROMAGNETIC RADIATION TO ACTIVATE FILTERCAKE BREAKERS DOWNHOLE | HORTON AMY C | 2010-10-21 | — | — | US | disclosed |
| EP-1870495-A1 | Aqueous alkaline, cyanide-free, bath for the galvanic deposition of Zinc and Zinc alloy layers | ATOTECH DEUTSCHLAND GMBH (DE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1355645-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040097495-A1 | Method for treating fibrotic diseases or other indications IIIC | WAGLE DILIP (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1355645-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | Alteon, Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020183365-A1 | Method for treating fibrotic diseases or other indications IIIC | ALTEON, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002067851-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097495-A1 | Method for treating fibrotic diseases or other indications IIIC | COL1A1, COL2A1, MMP1 | ACHE 3329/4885NPSR1 1325/4885L3MBTL1 2874/4885 |
| US-20020183365-A1 | Method for treating fibrotic diseases or other indications IIIC | EPX, COL2A1, COL1A1 | ACHE 3600/4885NPSR1 359/4885L3MBTL1 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.